NDA 013174 · Advanz Pharma
Dyrenium
Triamterene · Oral · Potassium-sparing Diuretic
NovelPriority reviewLast checked: Nov 19, 2026Latest source record: Feb 28, 2002 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1964
Aug 10, 1964
Approved uses
1
Original approval plus efficacy supplements
Registered trials
6
2 Phase 3, 1 recruiting
FAERS reports
7,328
4,003 serious, 414 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
Warnings Abnormal elevation of serum potassium levels (greater than or equal to 5.5 mEq/liter) can occur with all potassium-sparing agents, including Dyrenium. Hyperkalemia is more likely to occur in patients with renal impairment and diabetes (even without evidence of renal impairment), and in the elderly or severely ill. Since uncorrected hyperkalemia may be fatal, serum potassium levels must be monitored at frequent intervals especially in patients receiving Dyrenium, when dosages are changed or with any illness that may influence renal function. WARNINGS Abnormal elevation of serum potassium levels (greater than or equal to 5.5 mEq/liter) can occur with all potassium-sparing agents, including Dyrenium. Hyperkalemia is more likely to occur in patients with renal impairment and diabetes (even without evidence of renal impairment), and in the elderly or severely ill. Since uncorrected...
What it is approved for
From the label in effect Dec 5, 2024.
INDICATIONS AND USAGE Dyrenium (triamterene) is indicated in the treatment of edema associated with congestive heart failure, cirrhosis of the liver and the nephrotic syndrome; steroid-induced edema, idiopathic edema and edema due to secondary hyperaldosteronism. Dyrenium may be used alone or with other diuretics, either for its added diuretic effect or its potassium-sparing potential. It also promotes increased diuresis when patients prove resistant or only partially responsive to thiazides or other diuretics because of secondary hyperaldosteronism. Usage in Pregnancy . The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy, and there is no satisfactory evidence that they are useful in the treatment of developed toxemia. Edema during pregnancy may arise from pathological causes or from the physiologic and mechanical consequences of pregnancy. Diuretics are indicated in pregnancy (however, see PRECAUTIONS below) when edema is due to pathologic causes, just as they are in the absence of pregnancy. Dependent edema in pregnancy, resulting from restriction of venous return by the expanded uterus, is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is illogical and unnecessary. There is hypervolemia during normal pregnancy which is harmful to neither the fetus nor the mother (in the absence of cardiovascular disease), but which is associated with edema, including generalized edema, in the majority of pregnant women. If this edema produces discomfort, increased recumbency will often provide relief. In rare instances, this edema may cause extreme...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 10, 1964 Original approval · Type 1 - New Molecular Entity · priority review
2 products under this application
- DYRENIUM · TRIAMTERENE 100MG · CAPSULE, ORAL · Prescription · TE AB
- DYRENIUM · TRIAMTERENE 50MG · CAPSULE, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Triamterene" as an intervention, any sponsor and status, largest first.
- Action to Control Cardiovascular Risk in Diabetes (ACCORD)Pivotal-lookingCompleted
National Heart, Lung, and Blood Institute (NHLBI)NIH
NCT00000620 · 10,251 participants · Start Sep 1999 · Primary completion Jun 2009
Drug: Anti-hyperglycemic Agents; Anti-hypertensive Agents and 1 more · For: Atherosclerosis; Cardiovascular Diseases; Hypercholesterolemia and 4 more
Sites: Minneapolis, Minnesota; New York, New York; Winston-Salem, North Carolina · 7 sites in all
- Diuretics, Hypertension, and Arrhythmias Clinical TrialPivotal-lookingCompleted
University of California, San FranciscoAcademic, hospital or other
NCT00000525 · 233 participants · Start Jul 1986 · Primary completion Sep 1989
Drug: hydrochlorothiazide; triamterene and 1 more · For: Cardiovascular Diseases; Death, Sudden, Cardiac; Heart Arrest and 2 more
University of Southern DenmarkAcademic, hospital or other
NCT01918488 · 80 participants (planned) · Start Oct 2013 · Primary completion Dec 2014
Drug: Amiloride · For: Diabetic Nephropathies; Hypertension
Sites: Odense, Denmark
- Renin-Guided Therapeutics in the Management of Untreated, Uncontrolled, or Complicated HypertensionCompleted
Medical University of South CarolinaAcademic, hospital or other
NCT00684489 · 52 participants · Start Sep 2003 · Primary completion Mar 2005
Drug: clinical hypertension specialist-no specific med. Any anti-hypertension meds.; renin guided therapeutics-no specific med. Any anti-hypertensive med. · For: Hypertension
University of California, IrvineAcademic, hospital or other
NCT05582837 · 40 participants (planned) · Start Aug 1, 2022 · Primary completion Dec 30, 2027
Drug: nortriptyline + topiramate · For: Ménière
Sites: Orange, California
Georgetown UniversityAcademic, hospital or other
NCT02522650 · 30 participants (planned) · Start Jul 2013 · Primary completion Oct 2021
Drug: Amiloride; Triamterene · For: Proteinuria
Sites: Washington D.C., District of Columbia
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- chronic kidney disease479
- fatigue476
- drug ineffective453
- pain439
- nausea420
- diarrhoea405
- dyspnoea348
- dizziness345
- renal failure329
- headache327
- arthralgia314
- acute kidney injury308
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 144 |
| 2005 | 178 |
| 2006 | 154 |
| 2007 | 133 |
| 2008 | 152 |
| 2009 | 237 |
| 2010 | 323 |
| 2011 | 295 |
| 2012 | 312 |
| 2013 | 280 |
| 2014 | 384 |
| 2015 | 538 |
| 2016 | 487 |
| 2017 | 475 |
| 2018 | 664 |
| 2019 | 599 |
| 2020 | 405 |
| 2021 | 364 |
| 2022 | 308 |
| 2023 | 237 |
| 2024 | 237 |
| 2025 | 225 |
| 2026 | 197 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Dyrenium (Triamterene)
2024 spending
$262K
Beneficiaries
53
229 claims
Per beneficiary
$4,943
$13.40 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $797,218 |
| 2021 | $477,783 |
| 2022 | $322,966 |
| 2023 | $283,315 |
| 2024 | $261,979 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Pharmacotherapy for hypertension-induced left ventricular hypertrophy.
Leache L, Gutiérrez-Valencia M, Finizola RM, et al. · Cochrane Database Syst Rev 2021 · Research Support, Non-U.S. Gov't, Systematic Review
- A practical approach for measurement of antihypertensive medication adherence in patients with resistant hypertension.
Corrêa NB, de Faria AP, Ritter AM, et al. · J Am Soc Hypertens 2016 · Clinical Trial, Research Support, Non-U.S. Gov't
- Low dose loop diuretics in essential hypertension. Experience with torasemide.
Achhammer I, Metz P · Drugs 1991 · Clinical Trial, Comparative Study
- Maintenance of potassium balance during diuretic therapy.
Kohvakka A, Eisalo A, Manninen V · Acta Med Scand 1979 · Clinical Trial, Randomized Controlled Trial
- The Effect of Amiloride on Proteinuria in Patients with Proteinuric Kidney Disease.
Shen W, Alshehri M, Desale S, et al. · Am J Nephrol 2021 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Blood pressure lowering efficacy of potassium-sparing diuretics (that block the epithelial sodium channel) for primary hypertension.
Heran BS, Chen JM, Wang JJ, et al. · Cochrane Database Syst Rev 2012 · Meta-Analysis, Research Support, Non-U.S. Gov't
Sponsor: Advanz Pharma
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.